6. I wonder if there will be a proper insulin optimization phase lasting at least 6 weeks before patients are randomized in both groups? It is usually understood that 6 weeks of insulin optimization results in a significant drop in A1c from baseline to the point of randomization. The investigators may need to consider stratifying subjects by baseline A1c at the point of randomization. 7. The authors also wrote that time in range increased by a small percentage (7%) would translate into better outcomes. As much as I believe that is the future for patients requiring insulin therapy where the measurements should be TIR and other glucose variability indices; however, there is no consensus even by the regulators as to what is the standard. 8. Please note, some of the other authors have shown data for 1-2 years of use (please see the file attached) of hybrid closed-loop in real life and to that effect I'm wondering if a trial that only includes 6 months is good enough? 9. I think the authors should seriously consider the total study duration to be at least 8 months where insulin optimization phase is extended to 6 weeks, and full study duration lasting 24 weeks, followed by 3 weeks of masked CGM.
VERSION 1 -AUTHOR RESPONSE REVIEWER 1:
1. The EQ5D is not a measure of quality of life, it is a measure of functional health status. Please rephrase.
This has been rephrased.
2. I would urge the authors to reach out to the INSPIRE team and use the validated patient preference measures specific for automated insulin delivery systems for this trial.
We have reached out to the INSPIRE and have incorporated the INSPIRE questionnaire on automated insulin delivery systems expectations and experiences into our secondary measures. REVIEWER 2:
1. This is a design-only paper and includes no baseline data for the participants in the hybrid closedloop study.. Agreed, this is the purpose of the manuscript, protocol only.
2. The sample size is too small. There are a total of 97 subjects to be randomized into 2 different arms (subjects on MDI and pumps).
The authors are unsure where this reviewer found a total of 97 subjects. There are 160 subjects as stated in the manuscript, 80 with CSII at baseline and 80 with MDI at baseline. Power calculations have been described and are robust.
3. The study includes both pediatric and adult patients. The study inclusion criteria is 12 -25 years of age which meets the WHO criteria for young people. Indeed, the behaviour of this age group with respect to diabetes is very specific, and at the highest risk of poor control (See Miller et al Diabetes Care 2015) . The study was designed specifically to include this highest risk age band.
4. The inclusion criteria includes people with A1c <10.5%. It is commonly known that when patients have A1c >9% they are usually missing their boluses; thus I'm not sure including a group with such a high A1c with no stratification in the design will help in the final data analysis.
The groups are stratified on time in range as stated in the manuscript, and will therefore be balanced in the final data analysis.
5. Looking into the variables of subjects with different baseline A1cs, patients on MDI vs pumps, pediatric vs adults, I can foresee that at the end of the study each group will have a handful of patients to be analyzed in the final analysis.
The primary outcome is clearly stated, and we feel there is no potential for this to be split into small groups of patients. This study in young people will be analysed and published in an independent manner, as there are enough differences between this study and the parallel study in adults. A pooled analysis will follow, post hoc. Any sub-group analysis pertaining to the data from the described study in young people will be post-hoc.
6. I wonder if there will be a proper insulin optimization phase lasting at least 6 weeks before patients are randomized in both groups? It is usually understood that 6 weeks of insulin optimization results in a significant drop in A1c from baseline to the point of randomization. The investigators may need to consider stratifying subjects by baseline A1c at the point of randomization.
As described previously, subjects are stratified appropriately according to the primary objective, that being time in target range. There is a relatively close approximation between HbA1c and time in range that would make it unnecessary to also stratify on HbA1c.
7. The authors also wrote that time in range increased by a small percentage (7%) would translate into better outcomes. As much as I believe that is the future for patients requiring insulin therapy where the measurements should be TIR and other glucose variability indices; however, there is no consensus even by the regulators as to what is the standard.
Agreed, however we are presenting glycaemic data as per current reporting guidelines (Maahs et al, Diabetes Care 2016) 8. Please note, some of the other authors have shown data for 1-2 years of use (please see the file attached) of hybrid closed-loop in real life and to that effect I'm wondering if a trial that only includes 6 months is good enough? This data is uncontrolled, which is quite different from the RCT described and gives higher level evidence, particularly when considering health economic analysis.
9. I think the authors should seriously consider the total study duration to be at least 8 months where insulin optimization phase is extended to 6 weeks, and full study duration lasting 24 weeks, followed by 3 weeks of masked CGM.
Studies 6 month in duration have considerable precedent. Many new therapeutic diabetes studies show peak improvement at 3 months, with some deterioration between 3 to 6 months before reaching a plateau. Naturally, the longer study is, stronger conclusions can be made, however, study design does have an element of practicalities especially considering the cost of extending the study by 30%.
The length of optimization is particularly challenging, and there is no consensus on how long this should be -especially if we consider that at every routine (out of research) clinical visit we have the objective of "optimising" glycaemic control. By including stratification for time in range at randomisation, we are minimising bias that may affect the primary outcome. Further, longer duration studies are also challenging for the control arm of the study.
VERSION 2 -REVIEW

REVIEWER
Katharine Barnard Bournemouth University, UK REVIEW RETURNED 06-Dec-2017
GENERAL COMMENTS
Good luck with the study!
REVIEWER
Satish Garg
Barbara Davis Center for Diabetes<br>University of Colorado Denver REVIEW RETURNED 07-Dec-2017
GENERAL COMMENTS
My concerns are similar to the ones I raised in my previous review for this manuscript. There is no baseline data presented and the sample size is too small and the duration of the study is much shorter. It has been clearly shown in the literature that using hybrid closed-loop system improves glucose control reflected in A1c values and time-in-range. As I indicated previously, there's a much larger study that's ongoing, which has a large cohort of more than one thousand patients randomized into 3 different arms and is properly powered for the outcomes.
The discussion still mentions that this is the first large study comparing MDI, CSII (with or without CGM), and the role of HCL in 12-25 years old patients. Authors should be able to see on NCT.gov a much large study that's ongoing and the study duration is for 1 year. Many of the suggestions that I made in my previous review, authors have not considered those in their revised manuscript. For example, the study duration should be longer and there should be a significant phase of insulin optimization before patients are randomized.
REVIEWER
Yuan Wei Singapore Clinical Research Institute
REVIEW RETURNED
08-Feb-2018
GENERAL COMMENTS
In general, this protocol is well written. Study objective, study design, randomization procedure, power calculation, DSMB and statistical analysis plan are described in the protocol. A few statistical aspects of this protocol can be further improved.
1) Primary objective is well defined. There is a long list of secondary objectives. Although there is no clear cut of limit in number of secondary objectives that can be included in a study, having too many secondary objectives tends to make the study look like data fishing, especially for glucose control there are many endpoints of % time spent at different cut off values. It is unclear whether all or only some of the secondary objectives will be hypothesized and statistically tested, whether any multiple comparison approach will be used to handle so many secondary objectives if any claim is going to be made for secondary objectives, and whether some of the secondary endpoints are exploratory only.
2) More details need to be included for health economic analysis, i.e. prospective of the analysis, type of costs, sources of unit utilization and unit cost, time horizon, uncertainty, discounting if any.
3) There may be a typo in sample size calculation. On line 21 page 8, SD was 13%. On line 27 page 8, SD of 15% was used in the calculation. I tried to repeat the calculation using SD of 15% and I couldn't get 158 after considering 20% drop out. When I used SD of 13%, I got the same 158 as total sample size. Please verify if on line 27 it is a typo and it meant to be 13%. 4) There are five stratification factors for randomization. Five falls on the high side for stratified randomization especially considering the total sample size is only 158. Even though minimization is used to achieve balance across several prognostic factors, in practice minimization doesn't always guarantee balance. I wonder if there is sufficient clinical evidence that all the stratification factors are known prognostic factors and if the number of stratification factors can be reduced. 5) More details of minimization should be mentioned. It is unclear whether some elements of randomness are incorporated in the minimization algorithm to protect allocation concealment or the procedure is completely deterministic. 
Per the request of the editor, I reviewed the statistical aspects in this manuscript including the sample size calculation and the statistical analysis plan. The sample size calculation is correct and the statistical analysis plan is solid since they provided alternative plans if the normality assumption fails in the data.
The only question I have is about multiple testing. In the manuscript, the authors mentioned that they will consider a result "significant" is the unadjusted p-value is below 0.05. In my opinion, although it is OK to do so in the sample size calculation, while reporting the final result, multiple comparison should be considered if there are more than a handful of parallel statistical tests performed simultaneously. The author should list approximately how many parallel tests they plan to perform on the data and describe how they plan to adjust for the multiple comparison (or explain why they do not want to do so). 1. My concerns are similar to the ones I raised in my previous review for this manuscript. There is no baseline data presented and the sample size is too small and the duration of the study is much shorter. It has been clearly shown in the literature that using hybrid closed-loop system improves glucose control reflected in A1c values and time-in-range. As I indicated previously, there's a much larger study that's ongoing, which has a large cohort of more than one thousand patients randomized into 3 different arms and is properly powered for the outcomes.
VERSION 2 -AUTHOR RESPONSE
Response: We acknowledge that a larger study is ongoing, however this does not invalidate this RCT. We are adequately powered for our outcomes as described in the statistical analysis section.
2. The discussion still mentions that this is the first large study comparing MDI, CSII (with or without CGM), and the role of HCL in 12-25 years old patients. Authors should be able to see on NCT.gov a much large study that's ongoing and the study duration is for 1 year.
Response: This is now highlighted in the manuscript.
3. Many of the suggestions that I made in my previous review, authors have not considered those in their revised manuscript. For example, the study duration should be longer and there should be a significant phase of insulin optimization before patients are randomized.
Response: We have provided rebuttal for the suggestions, citing justifications for the study design and length. While we acknowledge that a very large and long term trial as currently underway by another group will give the most robust scientific evidence, such timelines carry risk due to the rapidly evolving technology and therefore diminishing the endurance of outcomes due to the technology being superseded by newer iterations. While we appreciate the suggestions, they do not invalidate the current study design. This study had external review from international experts as part of a protocol optimisation process. Further, the protocol has been reviewed by 2 statisticians below, and while there has been a request for clarification on some aspects, no design or outcome measurement analysis plan flaws have been raised.
Reviewer: 3 Reviewer Name: Yuan Wei Institution and Country: Singapore Clinical Research Institute Comments:
1. Primary objective is well defined. There is a long list of secondary objectives. Although there is no clear cut of limit in number of secondary objectives that can be included in a study, having too many secondary objectives tends to make the study look like data fishing, especially for glucose control there are many endpoints of % time spent at different cut off values. It is unclear whether all or only some of the secondary objectives will be hypothesized and statistically tested, whether any multiple comparison approach will be used to handle so many secondary objectives if any claim is going to be made for secondary objectives, and whether some of the secondary endpoints are exploratory only.
Reporting on the secondary outcomes, particularly the various glucose cut offs is standard in this field, and indeed is following the advice of a position statement on closed loop study outcome reporting. The readership for this protocol will expect these outcomes to be reported, and is line with other studies.
A number of secondary outcomes are exploratory and a number have supporting hypotheses; details on the secondary outcomes and planned analyses will be published in a separate Statistical Analysis Plan.
No adjustments for multiple comparisons will be applied, all results for primary and secondary outcomes will be reported (Schulz KF, Grimes DA. Multiplicity in randomised trials I: endpoints and treatments. Lancet 2005;365(9470):1591-5. doi: 10.1016/S0140-6736(05)66461-6). Publications arising from secondary outcomes analyses will indicate that the findings were generated from a larger study that tested a number of secondary outcomes.
2. More details need to be included for health economic analysis, i.e. prospective of the analysis, type of costs, sources of unit utilization and unit cost, time horizon, uncertainty, discounting if any.
Response: The health economic analysis is a complex undertaking, and is built from the various data that are collected. Due to the detail required, we are intending to supply the health economic analysis plan separately, as it will be reported separately, which is also due to limitations of content we can supply in this manuscript submission. We have made it clearer in the manuscript to communicate this.
3. There may be a typo in sample size calculation. On line 21 page 8, SD was 13%. On line 27 page 8, SD of 15% was used in the calculation. I tried to repeat the calculation using SD of 15% and I couldn't get 158 after considering 20% drop out. When I used SD of 13%, I got the same 158 as total sample size. Please verify if on line 27 it is a typo and it meant to be 13%.
Response: This is a typo, and has been corrected to 13%
4. There are five stratification factors for randomization. Five falls on the high side for stratified randomization especially considering the total sample size is only 158. Even though minimization is used to achieve balance across several prognostic factors, in practice minimization doesn't always guarantee balance. I wonder if there is sufficient clinical evidence that all the stratification factors are known prognostic factors and if the number of stratification factors can be reduced.
Response:
The stratifications were carefully considered, and there is evidence that each are prognostic factors:
i) target glucose range (above or below 55%) at baseline will be prognostic and as this is the primary outcome, needs to be stratified. ii) sex; while there is no evidence that sex confers different glycaemic control; adaptation to externally worn technologies may be different due to sex, and hence equal distribution of sex is important iii) age is a significant prognostic factor for glycaemic control, particular the teenage years conferring suboptimal glycaemic control iv) duration of diabetes; generally glycaemic control can deteriorate with time. v) trial site is an important issue, as site bias needs to be factored in a multi-site study.
5. More details of minimization should be mentioned. It is unclear whether some elements of randomness are incorporated in the minimization algorithm to protect allocation concealment or the procedure is completely deterministic.
Response:
Allocation concealment is protected though participant allocation being centrally managed by an independent third party (NHMRC Clinical Trials Centre) using their minimisation algorithm. More detail will be provided in a separate statistical analysis plan, as there is a restricted word count for this manuscript.
6. Will there be any pre-planned DSMB meeting? If so, at what time point? Are there any early stopping rules based on safety and efficacy? This should be mentioned in protocol.
Response: The stopping rules are set by the DSMB, who will meet quarterly. This is now clarified in the manuscript.
7. re per protocol and treated population going to be done as sensitivity analysis for primary endpoint? Why only baseline percentage score and site are adjusted for primary endpoint, but not other prognostic factors stratified in randomization? There are different opinions among statisticians in terms of whether or not randomization stratification factors should be adjusted in the primary analysis. Sensitivity analysis can be considered to include all factors stratified in randomization if authors have a strong reason why the factors should not be included in primary analysis.
This trial is being conducted concurrently with a randomised controlled trial of the same device in adults. The studies have an aligned core protocol and primary outcome analysis plan to facilitate comparison of results.
One difference across the studies is the number of balancing factors incorporated into the minimisation allocation. To align the analysis of the primary outcome across the studies, the primary analysis will not include minimisation factors. However, sensitivity analyses including all balancing factors will be conducted for the primary outcome.
8. How missing data will be handled for primary endpoint analysis?
Multiple imputation will be used to deal with missing data in the ITT analysis. This is clarified in the protocol.
Reviewer: 4 Reviewer Name: Chi Song Institution and Country: Ohio State University, USA Comments:
1. I reviewed the statistical aspects in this manuscript including the sample size calculation and the statistical analysis plan. The sample size calculation is correct and the statistical analysis plan is solid since they provided alternative plans if the normality assumption fails in the data.
The only question I have is about multiple testing. In the manuscript, the authors mentioned that they will consider a result "significant" is the unadjusted p-value is below 0.05. In my opinion, although it is OK to do so in the sample size calculation, while reporting the final result, multiple comparison should be considered if there are more than a handful of parallel statistical tests performed simultaneously. The author should list approximately how many parallel tests they plan to perform on the data and describe how they plan to adjust for the multiple comparison (or explain why they do not want to do so).
Details on the secondary outcomes and planned analyses will be published in a separate Statistical Analysis Plan.
No adjustments for multiple comparisons will be applied, all results for primary and secondary outcomes will be reported (Schulz KF, Grimes DA. 
GENERAL COMMENTS
The following points are my comments based on the revision. 1. There is a long list of secondary endpoints. The authors only mentioned analysis related to primary endpoint. A brief description how secondary endpoints will be analysed is needed. Whether or not multiple comparison will be corrected ( if no, reasons) should be included in the description. Multiple comparison may not always be needed for secondary endpoints, but in this study the list of secondary endpoints is long so it is good to discuss how it will be handled. 2. DSMB early stopping rules should be described in the study protocol.
3. Five randomization stratification factors falls on the high side in terms of number of stratification factors. Minimization doesn't always work. It is unclear whether some elements of randomness are incorporated in the minimization algorithm to protect allocation concealment or the procedure is completely deterministic.
REVIEWER
Chi Song
Ohio State University, USA REVIEW RETURNED 04-Apr-2018
GENERAL COMMENTS
The authors addressed all my comments.
VERSION 3 -AUTHOR RESPONSE
Please find the responses for these final queries below:
1. There is a long list of secondary endpoints. The authors only mentioned analysis related to primary endpoint. A brief description how secondary endpoints will be analysed is needed. Whether or not multiple comparison will be corrected ( if no, reasons) should be included in the description. Multiple comparison may not always be needed for secondary endpoints, but in this study the list of secondary endpoints is long so it is good to discuss how it will be handled.
Continuous secondary outcomes will be analysed using ANCOVA adjusting for baseline values, count outcomes will be analysed using Poisson regression (or negative binomial regression where overdispersion is apparent), and logistic regression will be used for binomial outcomes. Nonparametric methods will be used where model fit is poor and transformations are unsuccessful. Subgroup analysis by baseline insulin regimen will be performed by including an interaction term in the regression modelling, whereas where non-parametric methods are used, subgroup analysis will be performed by stratifying by baseline insulin regimen.
The long list of secondary outcomes is in line with the recommendations made by a recent consensus report for basic outcome measures to be reported in artificial pancreas trials (Maahs, et al, 2016) . The effectiveness of the intervention will be assessed based on the clearly specified primary outcome; secondary outcomes are exploratory in nature and will be labelled as such in publications arising from the study. No corrections for multiplicity are planned; rather, a transparent approach to reporting results will be taken, with all effects, confidence intervals, and p-values for the primary and secondary outcomes being presented (Schulz KF, et al 2005) . Results will be interpreted in light of the number of comparisons and where multiple comparisons indicate multiple effects, the consistency of these results will be discussed.
We believe taking a transparent approach, along with responsible interpretation of results, will sufficiently address limitations arising from multiple comparisons. 2. DSMB early stopping rules should be described in the study protocol
These are now provided.
Minimization has been shown to be an effective method for allocation in trials and is often superior to other methods in achieving balance between groups and still maintaining a high random component; especially in small trials and where there are a larger number of stratification factors. A large number of stratification factors may have an impact on achieved balance in a traditional stratified randomization approach (where cases are randomized across all combinations of levels of the stratification factors), having a much larger impact than does minimization (Chabouis, et al 2014) . As minimization is an allocation process there is no requirement on the number of patients in each of the crossed strata cells. For the number of strata levels used in this study, minimization will be effective in delivering minimal imbalance.
The minimization process used in this study does not include a probabilistic component; more details on the method can be found in Heritier, et al (2005) . Allocation concealment in this multi-site study is protected through the centralised management of participant allocation by an independent third party (the NHMRC Clinical Trials Centre): recruiters at each site do not have access to pooled strata information used in the minimization process, their access is restricted to their site participants, protecting allocation concealment and reducing the predictability of allocations. Whilst the study manager has access to the pooled data, this individual is separate from the recruitment process.
